Results of the ACTIVE-4a trial, which evaluated non-critically ill, hospitalized patients with COVID-19, found that the addition of a P2Y12 inhibitor to a therapeutic dose of heparin did not improve survival [20]. This evidence concerns the gene P2RY12 and COVID-19.